MASLD/MASH Screening and Diagnosis

CE / CME

MASLD/MASH Screening and Diagnosis

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: December 29, 2023

Expiration: December 28, 2024

Arun B. Jesudian
Arun B. Jesudian, MD

Activity

Progress
1 2
Course Completed

Introduction

In this module, Arun B. Jesudian, MD, discusses how to identify risk factors for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis. Learners also will focus on the current and emerging noninvasive liver assessment tests.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

How many patients with MASH do you provide care for in a typical week?

Which of the following is a strong clinical predictor of MASH and fibrosis?

A patient 55 years of age presents complaining of right upper quadrant discomfort and fatigue. The patient has a BMI of 26 kg/m2 and is taking metformin for type 2 diabetes and a statin for hyperlipidemia. The patient does not drink alcohol or smoke tobacco. Lab work reveals abnormal liver function tests. What should be the next step in patient care?